Why I Keep Buying These 10 Incredible Growth Stocks
These companies have bright futures and offer the potential for decades of share price appreciation.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Renaissance Group Opens New $35M Position in Halozyme Therapeutics ( NASDAQ: HALO ) : Why This Biotech Stock Is Worth a Look
On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics ( NASDAQ:HALO ) , acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC filing.According to a filing with the U.S.
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Halozyme ( HALO ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Nov. 3, 2025 at 4:30 p.m. ETPresident and Chief Executive Officer - Helen TorleyContinue reading ...
Halozyme Therapeutics ( HALO ) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. ( ANAB ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
Halozyme Therapeutics ( HALO ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will Halozyme Therapeutics ( HALO ) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Are Medical Stocks Lagging Armata Pharmaceuticals ( ARMP ) This Year?
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Why Halozyme Therapeutics ( HALO ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
Bull of the Day: Halozyme Therapeutics ( HALO )
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth ...
Halozyme Therapeutics ( HALO ) Is Up 2.63% in One Week: What You Should Know
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging atai Life Sciences ( ATAI ) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
This Top Medical Stock is a #1 ( Strong Buy ) : Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics ( HALO ) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stock to Buy for September 3rd
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Are Medical Stocks Lagging Halozyme Therapeutics ( HALO ) This Year?
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Halozyme Therapeutics, Inc. ( HALO ) Hit a 52 Week High, Can the Run Continue?
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
New Strong Buy Stocks for September 3rd
TDW, JRVR, HALO, SCSC and CSW have been added to the Zacks Rank #1 (Strong Buy) List on September 3, 2025.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Janus Henderson Small Cap Growth Alpha ETF ( JSML ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Janus Henderson Small Cap Growth Alpha ETF ( JSML ) Be on Your Investing Radar?
Style Box ETF report for ...
Why Halozyme Therapeutics ( HALO ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
